Table 1 Clinical and biologic... | American Society of Hematology

Table 1

Clinical and biologic characteristics of CLL patients

Characteristic	Value
Patients, n	400
Median age at diagnosis, y	60
Women/men, %	35/65
*Stage at time of TP53* and ATM examination (n = 365), %**
Low risk: Rai stage 0	30
Intermediate risk: Rai stage I/II	36
High risk: Rai stage III/IV	34
IgVH, % (n = 355)
Mutated	38
Unmutated	62
I-FISH according to the hierarchical classification of Döhner et al²⁶ (n = 400), %
17p−	11
11q−	21
+12	11
13q−	34
Normal	23
*Investigation of TP53* and ATM status, %**
At time of diagnosis	48
During course of disease	52
*Therapy before the first TP53* and ATM examination, %**
No	73
Yes	27

Characteristic	Value
Patients, n	400
Median age at diagnosis, y	60
Women/men, %	35/65
*Stage at time of TP53* and ATM examination (n = 365), %**
Low risk: Rai stage 0	30
Intermediate risk: Rai stage I/II	36
High risk: Rai stage III/IV	34
IgVH, % (n = 355)
Mutated	38
Unmutated	62
I-FISH according to the hierarchical classification of Döhner et al²⁶ (n = 400), %
17p−	11
11q−	21
+12	11
13q−	34
Normal	23
*Investigation of TP53* and ATM status, %**
At time of diagnosis	48
During course of disease	52
*Therapy before the first TP53* and ATM examination, %**
No	73
Yes	27

CLL indicates chronic lymphocytic leukemia; and I-FISH, interphase fluorescence in situ hybridization.